Drugs in Dev. Sleep
Phase I
Nxera Partner Centessa Reports Positive Ph 1 Data for ORX750 in Sleep-Deprived Volunteers
Details : ORX750 is an investigational, orally administered, highly potent and selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1.
Product Name : ORX750
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2024
Alkermes Announces Positive Phase 1b Results for ALKS 2680 in Narcolepsy Type 2 Patients
Details : ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist, which is being evaluated for the treatment of narcolepsy type 2 & idiopathic hypersomnia.
Product Name : ALKS 2680
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2024
EISAI TO BEGIN ENROLLING STUDY IN PATIENTS WITH NARCOLEPSY
Details : E2086 an oral novel selective orexin-2 agonist, being investigated for narcolepsy type I in adults. Nonclinical studies have demonstrated statistically significant reductions in rates of cataplexy.
Product Name : E2086
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 07, 2024
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
Details : ORX750 is an investigational, orally administered, highly potent and selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1.
Product Name : ORX750
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 30, 2024
Lead Product(s) : Acetazolamide,Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Phase I
Sponsor : Incannex Healthcare
Deal Size : Undisclosed
Deal Type : Partnership
Details : Fortrea will manage Incannex's IND opening Phase 2/3 clinical trial investigating IHL-42X which is a synergistic composition of dronabinol, a synthetic form of Tetrahydrocannabinol, and acetazolamide, a carbonic anhydrase inhibitor, for treatment of obst...
Product Name : IHL-42X
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 18, 2023
Lead Product(s) : Acetazolamide,Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase I
Sponsor : Incannex Healthcare
Deal Size : Undisclosed
Deal Type : Partnership
Details : Lysergic Acid Diethylamide is a potent psychoactive substance which binds to the 5-HT2A receptor as a partial agonist and 5-HT1A as an agonist. It is being investigated as Improves Sleep.
Product Name : MB22001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 14, 2023
Lead Product(s) : Acetazolamide,Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Pre-IND Meeting with US FDA for IHL-42X for Obstructive Sleep Apnoea
Details : IHL-42X (dronabinol) is a fixed-dose combination of dronabinol and acetazolamide that is being developed as a treatment for obstructive sleep apnoea (‘OSA’) in adults.
Product Name : IHL-42X
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : Acetazolamide,Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexmethylphenidate
Therapeutic Area : Sleep
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data suggest that KP1077 (serdexmethylphenidate) produces a smoother, more gradual release of d-MPH that may avoid the adverse events associated with large and rapid exposure fluctuations that may be experienced with other stimulant-based therapies.
Product Name : KP1077
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 05, 2022
Lead Product(s) : Dexmethylphenidate
Therapeutic Area : Sleep
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexmethylphenidate
Therapeutic Area : Sleep
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Prodrug of d-methylphenidate, is sole API in KP1077, a potential first-ever therapeutic treatment for Idiopathic Hypersomnia, a neurological disorder marked by significant, detrimental effects on nighttime sleep as well as daytime sleepiness/wakefulness.
Product Name : KP1077
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 19, 2022
Lead Product(s) : Dexmethylphenidate
Therapeutic Area : Sleep
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Under the agreement, Jazz will receive an exclusive license to develop and commercialize narcolepsy and sleep drug DSP-0187/JZP441 in U.S., Europe and other territories except Japan, China and other Asia/Pacific countries and regions, where Sumitomo Phar...
Product Name : JZP441
Product Type : Other Small Molecule
Upfront Cash : $50.0 million
April 05, 2022
Reset All
